Form 4: Merus Director Cashes Out Options in Genmab Tender Offer

Merus N.V. director Jason Haddock's share options were cancelled for cash following Genmab's successful tender offer at $97.00 per share.

Summary

• Jason Haddock, a Director of Merus N.V., reported changes in beneficial ownership via a Form 4 filing.
• The changes are a result of a tender offer by Genmab A/S, through its wholly owned subsidiary Genmab Holding II B.V., for all issued and outstanding common shares of Merus N.V.
• The tender offer consideration was $97.00 per share in cash, without interest and less applicable withholding taxes.
• On December 12, 2025, the Purchaser accepted all validly tendered shares as of the Acceptance Time.
• Haddock's share options were cancelled pursuant to the Transaction Agreement in exchange for a cash payment.
• The cash payment for options was calculated as the product of (Offer Consideration applicable exercise price per Share) and the aggregate number of Shares underlying such option.
• Specifically, 13,193 share options with an exercise price of $41.60 and an expiration date of May 22, 2035, were cancelled.
• Additionally, 17,688 share options with an exercise price of $48.73 and an expiration date of May 7, 2034, were cancelled.
• Following these transactions, Haddock beneficially owns 0 derivative securities.

Sentiment

Score: 8

Explanation: The filing reports a successful tender offer and a profitable cash-out for a director's options, indicating a positive outcome for shareholders and option holders involved in the acquisition.

Positives

• Director Jason Haddock received a cash payout for his share options, indicating a profitable exit for those options.
• The tender offer at $97.00 per share represents a significant premium over the exercise prices of the options ($41.60 and $48.73), resulting in substantial value realization for the option holder.

Negatives

• The cancellation of options means the director no longer holds a direct equity incentive in Merus N.V. through these specific instruments.
• The company's common shares are being acquired, indicating a change in ownership structure and the cessation of Merus N.V. as an independent publicly traded entity.

Future Outlook

The filing does not contain forward-looking statements or guidance, as it reports a past transaction related to a tender offer.

Industry Context

This filing indicates the successful acquisition of Merus N.V. by Genmab, a common occurrence in the biotechnology and pharmaceutical sectors where larger companies acquire smaller ones for their pipeline assets or technology. It reflects ongoing consolidation within the industry.

Comparison to Industry Standards

• The tender offer price of $97.00 per share for Merus N.V. common shares should be compared to recent M&A transactions in the biotech sector, considering the target company's stage of development, pipeline value, and market capitalization.
• For example, recent acquisitions like Pfizer's acquisition of Seagen for $43 billion (at $229 per share) or AbbVie's acquisition of ImmunoGen for $10.1 billion (at $31.26 per share) provide benchmarks for valuation multiples (e.g., enterprise value to peak sales, or premium to pre-announcement share price).
• The premium paid over the option exercise prices ($41.60 and $48.73) to the tender offer price ($97.00) suggests a significant value creation for option holders, which is typical in successful acquisitions.

Stakeholder Impact

• Shareholders: Received $97.00 per share in cash, providing liquidity and a premium for their shares.
• Option Holders (like Haddock): Received cash for their in-the-money options, realizing significant value.
• Company (Merus N.V.): Will become a subsidiary of Genmab, ceasing to be an independent publicly traded entity.

Next Steps

• Payment of the Offer Consideration to tendering shareholders as soon as practicable following the Acceptance Time (December 12, 2025).
• Finalization of the acquisition of Merus N.V. by Genmab.

Key Dates

Keywords

Merus N.V., MRUS, Genmab, Tender Offer, SEC Form 4, Beneficial Ownership, Share Options, Acquisition, Director Transaction, Equity Compensation